Show simple item record

dc.contributor.authorYildiz, Caglar
dc.contributor.authorKarakus, Savas
dc.contributor.authorBozoklu Akkar, Ozlem
dc.contributor.authorSahin, Ali
dc.contributor.authorBozkurt, Birkan
dc.contributor.authorYanik, Ali
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T09:44:17Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T09:44:17Z
dc.date.issued2017
dc.identifier.issn1309-0291
dc.identifier.issn2148-5046
dc.identifier.urihttps://dx.doi.org/10.5606/ArchRheumatol.2017.6066
dc.identifier.urihttps://hdl.handle.net/20.500.12418/7001
dc.descriptionWOS: 000406096700006en_US
dc.descriptionPubMed ID: 30375566en_US
dc.description.abstractObjectives: This study aims to evaluate the sexual function of females with primary Sjgren's syndrome (pSS) in comparison to healthy females by using the Female Sexual Function Index (FSFI). Patients and methods: This case-control study included 31 female patients (mean age 46.0 +/- 10.2 years; range 30 to 68 years) with pSS and 27 healthy females (mean age 44.2 +/- 8.5 years; range 30 to 55 years) as control group. The sexual function of the participants was assessed by 19-item FSFI. Results: Mean duration of pSS in the patient group was 35.9 months (range 3 to 264 months). Significantly higher number of pSS patients reported positive history for vaginal infection compared to controls (n= 26, 83.9% vs n= 7, 25.9%, respectively; p< 0.001) without any difference in endocervical culture result. Cervical smear assessment revealed more inflammation and atrophy in patient group compared to control group (p= 0.001). Mean FSFI total score was significantly lower in patient group than control group (18.9 +/- 9.9 vs 25.1 +/- 5.1, respectively; p=0.004). Similarly, five out of six domains of FSFI-arousal, lubrication, orgasm, satisfaction, and pain-were significantly lower in patient group. FSFI total and subscale scores, except for pain, were found to be negatively correlated with duration of pSS. Conclusion: The pSS causes sexual dysfunction in female patients. Furthermore, as disease duration increases, female sexual function decreases. Clinical management of female patients with pSS should cover the assessment of their sexual functionality and taking the necessary precautions to maintain satisfactory quality of life and treatment outcome.en_US
dc.language.isoengen_US
dc.publisherTURKISH LEAGUE AGAINST RHEUMATISMen_US
dc.relation.isversionof10.5606/ArchRheumatol.2017.6066en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDyspareuniaen_US
dc.subjectsexual functionen_US
dc.subjectSjogren's syndromeen_US
dc.titlePrimary Sjogren's Syndrome Adversely Affects the Female Sexual Function Assessed by the Female Sexual Function Index: A Case-Control Studyen_US
dc.typearticleen_US
dc.relation.journalARCHIVES OF RHEUMATOLOGYen_US
dc.contributor.department[Yildiz, Caglar -- Karakus, Savas -- Bozoklu Akkar, Ozlem -- Yanik, Ali] Cumhuriyet Univ, Dept Gynecol & Obstet, Med Fac, Sivas, Turkey -- [Sahin, Ali] Cumhuriyet Univ, Med Fac, Dept Internal Med, Div Rheumatol, Sivas, Turkey -- [Bozkurt, Birkan] Cumhuriyet Univ, Med Fac, Dept Gen Surg, Sivas, Turkeyen_US
dc.identifier.volume32en_US
dc.identifier.issue2en_US
dc.identifier.endpage128en_US
dc.identifier.startpage123en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record